Novo Nordisk steady momentum, obesity and diabetes powerhouse stock in global focus
26.06.2026 - 07:23:20 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 07:23.
Novo Nordisk A/S (DK0062498333) remains one of the most closely watched healthcare names in Europe. The Danish group is a heavyweight on the Copenhagen exchange and a key peer to US-listed Eli Lilly in the fast-growing obesity drug segment.
Analysts track GLP-1 growth
Analyst coverage remains intense as the company expands its GLP-1 franchise, led by semaglutide-based brands Ozempic and Wegovy. Major houses such as JPMorgan, Goldman Sachs and UBS regularly update their models to reflect prescription trends and capacity build-out in obesity and diabetes care.
Consensus data on platforms such as MarketScreener and other financial services show that a clear majority of analysts rate Novo Nordisk shares at Buy or equivalent, reflecting expectations of continued double-digit revenue growth from obesity therapies. Many models factor in further penetration in the United States and Europe, with additional upside from launches in other regions over the medium term.
Obesity drugs underpin long-term story
Novo Nordisk reports that demand for Wegovy in particular continues to exceed supply in several markets, and the company is investing heavily in manufacturing capacity to support future volume. Management has repeatedly highlighted GLP-1 medicines as the central driver for its long-term growth algorithm, both in diabetes and obesity treatment.
Obesity care has become a strategic pillar for the group, with clinical trial programs designed to document benefits beyond weight loss, including potential cardiovascular risk reduction. This strategic focus supports the investment case for Novo Nordisk shares as a structural growth story in global healthcare.
All news and analysis on the Novo Nordisk A/S shares
Track current articles, background and regulatory disclosures on Novo Nordisk A/S and keep an eye on developments in obesity and diabetes therapies.
How Novo Nordisk makes its money
Novo Nordisk generates the bulk of its revenue from diabetes care and obesity treatments, notably through injectable GLP-1 therapies such as Ozempic for type 2 diabetes and Wegovy for chronic weight management. The company also sells insulin products, rare disease therapies and other biopharmaceuticals.
Where the stock trades today
Novo Nordisk A/S stock trades on the Copenhagen exchange; the latest available quotations show the shares changing hands on Nasdaq Copenhagen in Danish kroner.
Novo Nordisk A/S at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- WKN: A3E9MZ
- Ticker: NOVO B
- Trading venue: Nasdaq Copenhagen
- Price (as of latest available close): data in Danish kroner on Nasdaq Copenhagen
- Market cap: one of the largest healthcare companies globally by market capitalization, measured in DKK
- Sector / industry: Healthcare - Pharmaceuticals / Biotechnology
- Index membership: OMX Copenhagen 25 and other Nordic and European healthcare benchmarks
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
